What is Otezla and what is it used for
Otezla is the brand name for apremilast, an oral small-molecule phosphodiesterase 4 (PDE4) inhibitor prescribed to adults with certain inflammatory conditions. It is approved to reduce signs and symptoms of plaque psoriasis, including scaling, redness, and itch, and to improve signs and symptoms of active psoriatic arthritis, such as joint pain, stiffness, and swelling. Otezla is also used to treat adult ulcerative colitis. Because it works inside cells to dampen specific inflammatory signals, it offers a targeted option for people whose skin or joint symptoms are not well controlled with other therapies. This profile explains how Otezla works, how it is used, and what to expect during treatment.
How Otezla works in the body
Otezla inhibits phosphodiesterase 4 (PDE4), an enzyme that breaks down cyclic adenosine monophosphate (cAMP). By blocking PDE4, Otezla raises intracellular cAMP levels, which reduces the release of inflammatory chemicals such as tumor necrosis factor-alpha (TNF-alpha), interleukin-17, and other cytokines. This dampening of inflammatory signaling helps slow the overactive immune responses that drive psoriasis, psoriatic arthritis, and ulcerative colitis. Unlike some biologic drugs that target a single cytokine, Otezla modulates multiple inflammatory mediators, which can be an advantage in conditions with complex immune pathways.
Key mechanism at a glance
- Inhibits PDE4 enzyme
- Increases intracellular cAMP
- Reduces inflammatory cytokine release
- Modulates immune cell activity
Approved indications and typical uses
Otezla is indicated for the treatment of adults with:
- Moderate-to-severe plaque psoriasis
- Active psoriatic arthritis
- Moderate-to-severe ulcerative colitis
For plaque psoriasis, Otezla can help clear skin lesions and relieve bothersome symptoms like itching and burning. In psoriatic arthritis, it may improve joint function and reduce pain and swelling. For ulcerative colitis, Otezla is used to induce and maintain remission in people who have not responded adequately to other treatments. A healthcare provider will consider disease severity, prior therapies, and patient preferences when deciding whether Otezla is appropriate.
Standard dosing and how to take it
Otezla is taken by mouth as a tablet. For plaque psoriasis and psoriatic arthritis, the usual dose is 30 mg twice daily. For ulcerative colitis, the recommended dose is 30 mg twice daily for the first four weeks, then 20 mg twice daily thereafter. Tablets can be taken with or without food. It is important to swallow the tablet whole with water and not to crush or chew it. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; in that case, skip the missed dose and resume the regular schedule. Do not double up to make up for a missed dose. Consistent use as prescribed helps maintain steady drug levels and supports long-term control of symptoms.
Potential side effects and safety considerations
Common side effects of Otezla include diarrhea, nausea, headache, vomiting, and stomach pain. Some people may experience changes in weight, appetite, or mood. Because Otezla affects immune signaling, it can slightly raise the risk of infections, so it is important to report persistent fever, cough, sore throat, or other signs of infection to a clinician. Rare but serious effects include depression or other mood changes, which in some cases have led to suicidal thoughts or actions. People with a history of mental health conditions should discuss this risk carefully with their provider. Before starting Otezla, tell your clinician about all medications you take and any history of depression, serious infections, or immune system problems. Regular follow-up visits help ensure that benefits continue to outweigh risks over time.
Practical management tips for people on Otezla
- Take the tablet at the same times each day to maintain steady levels.
- Use effective contraception during treatment and for a short period after stopping, as instructed by your clinician.
- Avoid stopping or dose changes suddenly without medical guidance.
- Keep a simple symptom log for skin, joints, or bowel habits to share with your clinician.
- Report any new or worsening mood changes, infections, or unusual symptoms promptly.
Otezla at a glance: key facts
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Drug class | Oral PDE4 inhibitor | Label |
| Typical adult dose (psoriasis/arthritis) | 30 mg twice daily | Label |
| Typical adult dose (ulcerative colitis) | 30 mg twice daily for 4 weeks, then 20 mg twice daily | Label |
| Common side effects | Diarrhea, nausea, headache, vomiting | Label |
| Serious risks | Mood changes, increased infection risk | Label |
| Route | Oral tablet | Label |
Otezla vs some alternative approaches
Otezla is a small-molecule option for people who prefer or require a non-biological oral therapy. Some clinicians consider it when biologics or phototherapy have not provided enough relief or when repeated injections or infusions are undesirable. Unlike systemic corticosteroids, Otezla does not cause the same type of short-term body-wide effects, but it is not suitable for everyone. Choice of therapy depends on disease severity, past responses, comorbidities, and patient lifestyle. A clinician can compare Otezla with other oral, biologic, and topical options to determine the best fit for an individual’s goals and risks.
When to contact your clinician
Contact your healthcare provider if you experience persistent diarrhea, unexplained weight loss, signs of infection, or mood changes while taking Otezla. Also seek medical attention for any severe stomach pain, blood in stool, or new or worsening joint symptoms. Regular check-ins allow dose adjustments, monitoring of effectiveness, and timely management of side effects. If you are considering stopping Otezla or switching therapies, discuss a taper plan with your clinician rather than changing the regimen on your own.
Summary and key takeaways
Otezla (apremilast) is an oral PDE4 inhibitor used to manage plaque psoriasis, psoriatic arthritis, and ulcerative colitis. By increasing cAMP and reducing inflammatory signaling, it can improve skin, joint, and bowel symptoms for many people. Common side effects include gastrointestinal symptoms and headache, while rare but serious effects involve mood changes and infection risk. Taking Otezla as prescribed, attending regular follow-ups, and reporting new symptoms promptly can help balance safety and effectiveness. This evergreen overview is intended to support long-term understanding of how Otezla works and how it is used in routine care.